740 related articles for article (PubMed ID: 31631384)
1. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
3. Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis.
Zhang SH; Zhao Y; Xie QB; Jiang Y; Wu YK; Yan B
Br J Dermatol; 2019 May; 180(5):1090-1098. PubMed ID: 29947075
[TBL] [Abstract][Full Text] [Related]
4. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
[TBL] [Abstract][Full Text] [Related]
5. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
6. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
[TBL] [Abstract][Full Text] [Related]
8. Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis.
Horai Y; Koga T; Fujikawa K; Takatani A; Nishino A; Nakashima Y; Suzuki T; Kawashiri SY; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Ida H; Kakugawa T; Sakamoto N; Ishimatsu Y; Mukae H; Hamaguchi Y; Fujimoto M; Kuwana M; Origuchi T; Kohno S; Kawakami A
Mod Rheumatol; 2015 Jan; 25(1):85-9. PubMed ID: 24716595
[TBL] [Abstract][Full Text] [Related]
9. Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
Matsuda KM; Yoshizaki A; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Sato S
J Dermatol; 2020 May; 47(5):483-489. PubMed ID: 32096271
[TBL] [Abstract][Full Text] [Related]
10. Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis.
Kobayashi N; Kobayashi I; Mori M; Sato S; Iwata N; Shigemura T; Agematsu K; Yokota S; Koike K
J Rheumatol; 2015 Dec; 42(12):2412-8. PubMed ID: 26472413
[TBL] [Abstract][Full Text] [Related]
11. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis.
Gono T; Kawaguchi Y; Satoh T; Kuwana M; Katsumata Y; Takagi K; Masuda I; Tochimoto A; Baba S; Okamoto Y; Ota Y; Yamanaka H
Rheumatology (Oxford); 2010 Sep; 49(9):1713-9. PubMed ID: 20498012
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease.
Fukada A; Fujisawa T; Hozumi H; Koda K; Akamatsu T; Oyama Y; Satake Y; Niwa M; Kaida Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Hashimoto D; Yoshida A; Gono T; Kuwana M; Yamano Y; Kondoh Y; Yamashita K; Maekawa M; Mori K; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Inui N; Suda T
Arthritis Rheumatol; 2024 May; 76(5):796-805. PubMed ID: 38146102
[TBL] [Abstract][Full Text] [Related]
14. The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients.
Ono N; Kai K; Maruyama A; Sakai M; Sadanaga Y; Koarada S; Inoue T; Tada Y
Rheumatology (Oxford); 2019 May; 58(5):786-791. PubMed ID: 30541137
[TBL] [Abstract][Full Text] [Related]
15. Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis.
Nishioka A; Tsunoda S; Abe T; Yoshikawa T; Takata M; Kitano M; Matsui K; Nakashima R; Hosono Y; Ohmura K; Mimori T; Sano H
Mod Rheumatol; 2019 Sep; 29(5):814-820. PubMed ID: 30449228
[No Abstract] [Full Text] [Related]
16. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
[TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S
Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
[TBL] [Abstract][Full Text] [Related]
18. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis.
Zuo Y; Ye L; Liu M; Li S; Liu W; Chen F; Lu X; Gordon P; Wang G; Shu X
Rheumatology (Oxford); 2020 Oct; 59(10):2829-2837. PubMed ID: 32065646
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease.
Motegi SI; Sekiguchi A; Toki S; Kishi C; Endo Y; Yasuda M; Ikeuchi H; Sakairi T; Hara K; Yamaguchi K; Maeno T; Hiromura K; Ishikawa O
Eur J Dermatol; 2019 Oct; 29(5):511-517. PubMed ID: 31617496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
